Neumora Therapeutics, Inc. (NMRA): Total Assets
$191.05M
As of 2025-12-31
$125.25M
As of 2026-06-30
-23.5%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $191.05M | -39.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $316.97M | -36.1% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $496.19M | +16.4% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $426.23M | n/a | 2024-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $191.05M | -39.7% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $181.20M | +83.8% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $203.52M | -22.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $175.37M | -44.0% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $209.47M | +15.4% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $172.81M | +291.0% |
Compare NMRA, EDIT, VXRT, IKT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗